BIO
Bio-Rad LaboratoriesDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
Current thesis
The bull case is that core operations are proving more durable than the headline GAAP loss suggests: Q1 reported sales still grew, Bio-Rad remained cash generative, repurchased shares, and activist involvement may sharpen capital-allocation discipline.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-30 · AMC.
What can break
Academic research demand remains soft, especially in the Americas, pressuring constant-currency Life Science growth. [#SEC-8K-2026-04-30]
Momentum
33
Value
64
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $305.00 · Bull $340.00 · Bear $245.00
Earnings
2026-07-30 · AMC
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $301.25
Why
Momentum33 · Δ7d +11.4
Value64 · Δ7d -0.5
Sentiment41 · Δ7d -4.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
33
26% active weight
Current posture
7d trendImproving
Δ7d
+11.4
Δ21d
-0.3
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.6
Sentiment
41
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-5.6
Why this grade
Composite grade D. Momentum 32.9 / Value 63.6 / Sentiment 40.6
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$8.53B
Beta
1.18
Shares Out
26.76M
P/E (TTM)
27.2
P/S (TTM)
3.38
P/FCF (TTM)
25.65
Rev YoY
+1.1%
EPS YoY
-954.0%
Gross Margin
+51.8%
Op Margin
+8.5%
Net Debt
-$157.4M
Current Ratio
3.21
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology